Men with severe hemophilia in the United States: birth cohort analysis of a large national database
- PMID: 26983851
- PMCID: PMC4911863
- DOI: 10.1182/blood-2015-10-675140
Men with severe hemophilia in the United States: birth cohort analysis of a large national database
Abstract
The availability of longitudinal data collected prospectively from 1998 to 2011 at federally funded US hemophilia treatment centers provided an opportunity to construct a descriptive analysis of how outcomes of men with severe hemophilia have been altered by the incremental advances and setbacks in hemophilia care in the last 50 years in the United States. This surveillance collaboration with the US Centers for Disease Control and Prevention assembled the largest uniformly examined population with severe hemophilia (n = 4899 men with severe factor VIII and IX deficiency). To address the heterogeneity of this population, 4 successive birth cohorts, differentially affected by eras of hemophilia care, were examined separately in regard to demographics, complications of hemophilia and its treatment, and mortality. Severely affected men in each birth cohort were compared also with the corresponding mild hemophilia birth cohorts (n = 2587 men total) to control for outcomes that might be attributable to aging and environment independent of severely defective hemostasis. The analysis demonstrates improving access to standard of care therapy, correlating the proportion of men on prophylactic factor replacement and reduced bleeding frequency for the youngest men. Frequent bleeding persisted in one third to one half of men across all ages, however, and the disability gap between severe and mild hemophilia did not narrow. The greatest cause of death was liver failure, but attempted anti-hepatitis C virus therapy and cure were low. The study suggests a continued need for national surveillance to monitor and inform hemophilia interventions and outcomes.
Figures
Comment in
-
Hemophilia: a cautionary status report.Blood. 2016 Jun 16;127(24):2949-50. doi: 10.1182/blood-2016-03-707117. Blood. 2016. PMID: 27313325 No abstract available.
Similar articles
-
Hemophilia care in China: review of care for 417 hemophilia patients from 11 treatment centers in Shanxi Province.Expert Rev Hematol. 2015 Aug;8(4):543-50. doi: 10.1586/17474086.2015.1043263. Epub 2015 May 6. Expert Rev Hematol. 2015. PMID: 25948487
-
Adherence to clotting factors among persons with hemophilia A or B.Hematology. 2015 Apr;20(3):148-53. doi: 10.1179/1607845414Y.0000000176. Epub 2014 Jul 7. Hematology. 2015. PMID: 25001343
-
Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience.Haemophilia. 2017 Sep;23(5):e403-e408. doi: 10.1111/hae.13302. Epub 2017 Jul 31. Haemophilia. 2017. PMID: 28758324
-
Hemophilia and cancer: a new challenge for hemophilia centers.Cancer Treat Rev. 2009 Jun;35(4):374-7. doi: 10.1016/j.ctrv.2009.01.001. Epub 2009 Feb 4. Cancer Treat Rev. 2009. PMID: 19195788 Review.
-
Hemophilia in the managed care setting.Am J Manag Care. 2015 Mar;21(6 Suppl):S123-30. Am J Manag Care. 2015. PMID: 26168207 Review.
Cited by
-
The prevalence of Hemophilia A in males in Africa: evidence from a systematic review and meta-analysis.BMC Public Health. 2024 Sep 27;24(1):2582. doi: 10.1186/s12889-024-20165-w. BMC Public Health. 2024. PMID: 39334048 Free PMC article.
-
Roctavian gene therapy for hemophilia A.Blood Adv. 2024 Oct 8;8(19):5179-5189. doi: 10.1182/bloodadvances.2023011847. Blood Adv. 2024. PMID: 38991118 Free PMC article. Review.
-
Optimizing liver health before and after gene therapy for hemophilia A.Blood Adv. 2024 Oct 8;8(19):5203-5212. doi: 10.1182/bloodadvances.2024013059. Blood Adv. 2024. PMID: 38843379 Free PMC article. Review.
-
The imperative to prevent joint bleeding in everyone living with hemophilia.Res Pract Thromb Haemost. 2024 Mar 15;8(2):102383. doi: 10.1016/j.rpth.2024.102383. eCollection 2024 Feb. Res Pract Thromb Haemost. 2024. PMID: 38590364 Free PMC article. No abstract available.
-
Surgical Emergencies in Patients with Hemophilia A-What to Expect.Healthcare (Basel). 2024 Mar 7;12(6):610. doi: 10.3390/healthcare12060610. Healthcare (Basel). 2024. PMID: 38540574 Free PMC article.
References
-
- Evatt BL. The natural evolution of haemophilia care: developing and sustaining comprehensive care globally. Haemophilia. 2006;12(Suppl 3):13–21. - PubMed
-
- Evatt BL. The tragic history of AIDS in the hemophilia population, 1982-1984. J Thromb Haemost. 2006;4(11):2295–2301. - PubMed
-
- Public Law 9463: The Public Health Service Act Establishing the Hemophilia Diagnostic and Treatment Center Program. N01131 of Public Law 9463. Washington, DC: Government Printing Office; 1975.
-
- Soucie JM, McAlister S, McClellan A, Oakley M, Su Y. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med. 2010;38(4 Suppl):S475–S481. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous

